Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
53actual
Sites
62
Countries
Austria, Czechia, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-19 | actual | When the study began enrolling |
| Primary completion | 2024-07-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-02-03 | actual | When this record first appeared on the registry |
| Results posted | 2025-07-28 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diffuse Large B Cell Lymphoma
Interventions
- Drug: Tafasitamab — also filed as INCMOR00208, MOR00208, Xmab5574
- Drug: Lenalidomide
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)
measured up to approximately 2 years
Number of Participants With Any ≥Grade 3 TEAE
measured up to approximately 2 years
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-04-11 · 1.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-10-24 · 652 KB · SAP_001.pdf
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed